Dewey Steadman on marketing regulation
From Pulling Focus | Dewey Steadman - United Therapeutics · · Press Record Media
“On the marketing side we're in a highly regulated environment and FDA dictates a lot of what we can say and can't say in our marketing materials.”
On , Dewey Steadman, Head of Investor Relations at UNITED THERAPEUTICS CORP, spoke about marketing regulation during Pulling Focus | Dewey Steadman - United Therapeutics on Press Record Media.
About Dewey Steadman
Dewey Steadman, Head of Investor Relations at United Therapeutics, discussed the company's growth and communication strategy in a February 2025 podcast. He stated that since joining the company five years ago, United Therapeutics more than doubled its revenue run rate, tripled its share price, and increased its employee count by approximately 50%. Steadman described his role as the primary spokesperson for both investor and media relations, and noted that the company is a public benefit corporation, which he said allows it to consider patients, shareholders, employees, and communities equally in corporate decisions. Steadman said the company aims to create value with "the right investors" rather than driving up the stock price with a generic presentation. He acknowledged that the company has not implemented standard marketing metrics such as click-through rates, but has received anecdotal feedback from investors who appreciate video content, particularly about the company's Phase 5 Net Zero Warehouse and its designated pathogen free facility. He also noted that the brand is managed by the general counsel's office, separate from commercial product marketing, and that the company operates in a highly regulated environment where the FDA dictates much of what can be said in marketing materials.